Aquila up on adjuvant data

AQLA shares rose $3.563 (136 percent) to $6.188 on Wednesday after University of Rochester researchers presented data from 60 healthy volunteers showing that 0.5 or 3 ug of a monovalent gp120 HIV vaccine, or 6 ug of a divalent gp120 vaccine, formulated with AQLA's QS-21 adjuvant, gave similar immunogenicity compared to historical data with vaccines of 100 ug gp120 formulated with alum. AQLA suggested that use of QS-21 could reduce amounts of antigen required for vaccine development. Data were presented at the International AIDS Conference in Durban. ...